Palvella Therapeutics (PVLA) Profit After Tax (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Profit After Tax of -$15.8 million for Q1 2026, down 92.28% year-over-year from -$204.2 million in Q1 2025, and down 23.81% quarter-over-quarter from -$12.7 million in Q4 2025.
Palvella Therapeutics (PVLA) Profit After Tax (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Profit After Tax for 14 consecutive years, with -$15.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 92.28% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$49.3 million (down 111.74% YoY), while the FY2025 annual figure was -$41.6 million, down 138.81% from the prior year.
- Profit After Tax declined to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $38.0 million in Q4 2023 and bottomed at -$15.8 million in Q1 2026.
- Historically, Profit After Tax has averaged -$5.3 million across 5 years, with a median of -$8.2 million in 2025.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 585.41% — and 2025, when it tumbled 223.34%.
- Palvella Therapeutics' Profit After Tax stood at -$7.8 million in 2022, then soared by 585.41% to $38.0 million in 2023, then tumbled by 110.41% to -$4.0 million in 2024, then slumped by 222.32% to -$12.7 million in 2025, then decreased by 23.81% to -$15.8 million in 2026.
- Business Quant data shows PVLA's Profit After Tax at -$15.8 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | -21.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.88 Mn |
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | -12.74 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Dec 31, 2024 | -3.95 Mn |
| Sep 30, 2024 | -6.97 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | 37.96 Mn |
| Sep 30, 2023 | -10.80 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | -13.18 Mn |
| Dec 31, 2022 | -7.82 Mn |
| Sep 30, 2022 | -9.74 Mn |
| Jun 30, 2022 | -10.30 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | -8.41 Mn |
| Sep 30, 2021 | -16.50 Mn |